Core Viewpoint - 微泰医疗-B (02235) reported significant growth in revenue and gross profit for the first half of 2025, driven by increased sales of glucose monitoring systems both domestically and internationally [1] Financial Performance - Revenue reached approximately 246 million yuan, representing a year-on-year increase of 63.1% [1] - Gross profit was about 127 million yuan, showing a year-on-year growth of 57.7% [1] - The loss attributable to the parent company was approximately 2.29 million yuan, narrowing by 93.9% year-on-year [1] - Earnings per share reflected a loss of 0.005 yuan [1] Operational Efficiency - The reduction in net loss was primarily due to the expansion of the company's sales scale, enhanced budget control, and improved operational efficiency through refined management practices [1]
微泰医疗-B公布中期业绩 母公司拥有人应占亏损约229.27万元 同比收窄93.9%